{"id":173378,"date":"2026-08-10T10:06:38","date_gmt":"2026-08-10T10:06:38","guid":{"rendered":"https:\/\/www.m3globalresearch.com\/blog\/?p=173378"},"modified":"2026-08-11T16:40:27","modified_gmt":"2026-08-11T16:40:27","slug":"pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials","status":"publish","type":"post","link":"https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/","title":{"rendered":"Oral JAK Inhibitor Shows Promise for Vitiligo in Phase 3 Trials"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n \t\t
\n\t\t\t\t\t\t\t\t\t

A positive Phase 3 trial results has been announced for a new oral medication (ritlecitinib), reporting that the drug helped restore skin pigmentation in people with nonsegmental vitiligo, including patients with longstanding or advanced disease. The company plans to submit data to health authorities for review.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

The clinical programme met its primary and key secondary endpoints, demonstrating statistically significant improvements in skin repigmentation compared with placebo. One primary measure was the Facial Vitiligo Area Scoring Index (F-VASI), which evaluates facial pigmentation improvements. Patients receiving it achieved significantly greater facial repigmentation than those receiving placebo, with improvements becoming more pronounced over the course of treatment.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

Encouraging responses were also observed among patients with more advanced or longstanding disease, an area where treatment options have traditionally been limited. The drug’s safety profile was generally consistent with previous studies of Litfulo for alopecia areata, for which it is already approved in several countries.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

Vitiligo is a chronic autoimmune condition in which the immune system attacks melanocytes, the cells responsible for producing melanin. As melanocytes are lost, patches of lighter or white skin develop, often appearing symmetrically on the face, hands, and arms. Although not physically painful, vitiligo can have significant psychological and social impact.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

It is a Janus kinase (JAK) inhibitor, working by interfering with immune signalling involved in autoimmune inflammation. Current vitiligo treatments include topical corticosteroids, topical JAK inhibitors such as ruxolitinib, calcineurin inhibitors, and phototherapy.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

If approved, it could become the first oral treatment specifically authorised for nonsegmental vitiligo, potentially offering an important option for patients who have not responded adequately to existing therapies.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

Source: Nature World News \/ Pfizer (2026)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Oral JAK inhibitor shows significant skin repigmentation in Phase 3 vitiligo trials, potentially becoming first oral treatment for condition.<\/p>\n","protected":false},"author":11,"featured_media":173436,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_eb_attr":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[3200],"tags":[],"class_list":["post-173378","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-medical-news"],"acf":[],"yoast_head":"\nOral JAK Inhibitor Shows Promise for Vitiligo in Phase 3 Trials<\/title>\n<meta name=\"description\" content=\"Oral JAK inhibitor shows significant skin repigmentation in Phase 3 vitiligo trials, potentially becoming first oral treatment for condition.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oral JAK Inhibitor Shows Promise for Vitiligo in Phase 3 Trials\" \/>\n<meta property=\"og:description\" content=\"Filtered coffee and instant coffee show different links to biological ageing, highlighting how brewing methods may influence healthy ageing.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"M3 Global Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/en-gb.facebook.com\/M3GlobalResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T10:06:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-11T16:40:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/08\/Litfulo-scaled.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Admin B.\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"TAVR matches open-heart surgery durability in low-risk patients, as PARTNER 3 trial seven-year data confirm lasting valve performance.\" \/>\n<meta name=\"twitter:creator\" content=\"@M3GR_Community\" \/>\n<meta name=\"twitter:site\" content=\"@M3GR_Community\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Admin B.\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\\\/\"},\"author\":{\"name\":\"Admin B.\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#\\\/schema\\\/person\\\/2694d930280885a6f8adfd3c7090c10b\"},\"headline\":\"Oral JAK Inhibitor Shows Promise for Vitiligo in Phase 3 Trials\",\"datePublished\":\"2026-08-10T10:06:38+00:00\",\"dateModified\":\"2026-08-11T16:40:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\\\/\"},\"wordCount\":278,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.m3globalresearch.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Litfulo-scaled.jpeg?fit=2560%2C1707&ssl=1\",\"articleSection\":[\"Latest Medical News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\\\/\",\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\\\/\",\"name\":\"Oral JAK Inhibitor Shows Promise for Vitiligo in Phase 3 Trials\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.m3globalresearch.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Litfulo-scaled.jpeg?fit=2560%2C1707&ssl=1\",\"datePublished\":\"2026-08-10T10:06:38+00:00\",\"dateModified\":\"2026-08-11T16:40:27+00:00\",\"description\":\"Oral JAK inhibitor shows significant skin repigmentation in Phase 3 vitiligo trials, potentially becoming first oral treatment for condition.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/www.m3globalresearch.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Litfulo-scaled.jpeg?fit=2560%2C1707&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.m3globalresearch.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Litfulo-scaled.jpeg?fit=2560%2C1707&ssl=1\",\"width\":2560,\"height\":1707,\"caption\":\"Pfizer reports positive phase 3 trial results for litfulo (ritlecitinib), showing restored pigmentation in people with nonsegmental vitiligo.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oral JAK Inhibitor Shows Promise for Vitiligo in Phase 3 Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/\",\"name\":\"M3 Global Research\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#organization\",\"name\":\"M3 Global Research\",\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":null,\"contentUrl\":null,\"width\":null,\"height\":null,\"caption\":\"M3 Global Research\"},\"image\":{\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/en-gb.facebook.com\\\/M3GlobalResearch\\\/\",\"https:\\\/\\\/x.com\\\/M3GR_Community\",\"https:\\\/\\\/www.instagram.com\\\/m3globalresearch\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/10557915\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/#\\\/schema\\\/person\\\/2694d930280885a6f8adfd3c7090c10b\",\"name\":\"Admin B.\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g\",\"caption\":\"Admin B.\"},\"url\":\"https:\\\/\\\/www.m3globalresearch.com\\\/blog\\\/author\\\/admin-b\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Oral JAK Inhibitor Shows Promise for Vitiligo in Phase 3 Trials","description":"Oral JAK inhibitor shows significant skin repigmentation in Phase 3 vitiligo trials, potentially becoming first oral treatment for condition.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/","og_locale":"en_US","og_type":"article","og_title":"Oral JAK Inhibitor Shows Promise for Vitiligo in Phase 3 Trials","og_description":"Filtered coffee and instant coffee show different links to biological ageing, highlighting how brewing methods may influence healthy ageing.","og_url":"https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/","og_site_name":"M3 Global Research","article_publisher":"https:\/\/en-gb.facebook.com\/M3GlobalResearch\/","article_published_time":"2026-08-10T10:06:38+00:00","article_modified_time":"2026-08-11T16:40:27+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/08\/Litfulo-scaled.jpeg","type":"image\/jpeg"}],"author":"Admin B.","twitter_card":"summary_large_image","twitter_description":"TAVR matches open-heart surgery durability in low-risk patients, as PARTNER 3 trial seven-year data confirm lasting valve performance.","twitter_creator":"@M3GR_Community","twitter_site":"@M3GR_Community","twitter_misc":{"Written by":"Admin B.","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/#article","isPartOf":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/"},"author":{"name":"Admin B.","@id":"https:\/\/www.m3globalresearch.com\/blog\/#\/schema\/person\/2694d930280885a6f8adfd3c7090c10b"},"headline":"Oral JAK Inhibitor Shows Promise for Vitiligo in Phase 3 Trials","datePublished":"2026-08-10T10:06:38+00:00","dateModified":"2026-08-11T16:40:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/"},"wordCount":278,"commentCount":0,"publisher":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/#organization"},"image":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/08\/Litfulo-scaled.jpeg?fit=2560%2C1707&ssl=1","articleSection":["Latest Medical News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/","url":"https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/","name":"Oral JAK Inhibitor Shows Promise for Vitiligo in Phase 3 Trials","isPartOf":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/#primaryimage"},"image":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/08\/Litfulo-scaled.jpeg?fit=2560%2C1707&ssl=1","datePublished":"2026-08-10T10:06:38+00:00","dateModified":"2026-08-11T16:40:27+00:00","description":"Oral JAK inhibitor shows significant skin repigmentation in Phase 3 vitiligo trials, potentially becoming first oral treatment for condition.","breadcrumb":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/#primaryimage","url":"https:\/\/i0.wp.com\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/08\/Litfulo-scaled.jpeg?fit=2560%2C1707&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/08\/Litfulo-scaled.jpeg?fit=2560%2C1707&ssl=1","width":2560,"height":1707,"caption":"Pfizer reports positive phase 3 trial results for litfulo (ritlecitinib), showing restored pigmentation in people with nonsegmental vitiligo."},{"@type":"BreadcrumbList","@id":"https:\/\/www.m3globalresearch.com\/blog\/pfizers-oral-jak-inhibitor-shows-promise-for-vitiligo-in-phase-3-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.m3globalresearch.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Oral JAK Inhibitor Shows Promise for Vitiligo in Phase 3 Trials"}]},{"@type":"WebSite","@id":"https:\/\/www.m3globalresearch.com\/blog\/#website","url":"https:\/\/www.m3globalresearch.com\/blog\/","name":"M3 Global Research","description":"","publisher":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.m3globalresearch.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.m3globalresearch.com\/blog\/#organization","name":"M3 Global Research","url":"https:\/\/www.m3globalresearch.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.m3globalresearch.com\/blog\/#\/schema\/logo\/image\/","url":null,"contentUrl":null,"width":null,"height":null,"caption":"M3 Global Research"},"image":{"@id":"https:\/\/www.m3globalresearch.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/en-gb.facebook.com\/M3GlobalResearch\/","https:\/\/x.com\/M3GR_Community","https:\/\/www.instagram.com\/m3globalresearch","https:\/\/www.linkedin.com\/company\/10557915"]},{"@type":"Person","@id":"https:\/\/www.m3globalresearch.com\/blog\/#\/schema\/person\/2694d930280885a6f8adfd3c7090c10b","name":"Admin B.","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5f811bebef837ff0367d28aa777df5c8b43795cab6f9ff385cce49abb4e04a6f?s=96&d=mm&r=g","caption":"Admin B."},"url":"https:\/\/www.m3globalresearch.com\/blog\/author\/admin-b\/"}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.m3globalresearch.com\/blog\/wp-content\/uploads\/2026\/08\/Litfulo-scaled.jpeg?fit=2560%2C1707&ssl=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/posts\/173378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/comments?post=173378"}],"version-history":[{"count":23,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/posts\/173378\/revisions"}],"predecessor-version":[{"id":173544,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/posts\/173378\/revisions\/173544"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/media\/173436"}],"wp:attachment":[{"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/media?parent=173378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/categories?post=173378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.m3globalresearch.com\/blog\/wp-json\/wp\/v2\/tags?post=173378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}